11th October 2017 – Yokohama, Japan – Sygnature Discovery, the UK’s largest independent provider of integrated drug discovery resource and expertise, is participating in BioJapan 2017 from 11th – 13th October 2017 in Yokohama. Sygnature is part of a UK Department of International Trade (UK DIT) Mission and is located on the UK Pavilion (Booth No. C-48).
The Sygnature Discovery BioJapan team is being led by Dr Steve Young, VP, Business Development. He is accompanied by Dr Mihiro Sunose, Principal Scientist, Chemistry, and Dr Hiroki Wada, Senior Scientist, Chemistry.
Dr Young commented, “Sygnature Discovery sees a great business opportunity to collaborate with pharmaceutical and biotechnology companies located in Japan. We are already working with a number of Japanese companies and our integrated service-offering co-located in our new, purpose-built facility at BioCity Nottingham has been beneficial to their projects. In addition, having Mihiro and Hiroki as part of our team enables us to communicate effectively with our clients in Japan. We are pleased to be part of the UK DIT mission and anticipate a successful time at BioJapan 2017.”
As well as taking part in BioJapan 2017, the Sygnature team will also be meeting with clients and potential clients whilst in Japan.